REPRISE III Trial: Analysis of Predictors of Stroke

As shown in the REPRISE III data, the LOTUS Valve showed a significantly lower disabling stroke rate and a numerically lower overall stroke rate.

  LOTUS Evolut R / CoreValve P Value
Stroke 7.5% 9.8% P = 0.28
Disabling Stroke 4.0% 7.4% P = 0.03

Presented by A. Linke, MD at EuroPCR 2018

In this analysis, predictors of late stroke included:

Multivariate analysis including baseline parameters only

  P Value
Ejection Fraction 0.01
Treatment with Evolut R / CoreValve 0.01

 

Multivariate analysis including 30-day parameters

Mild or Greater PVL at 30 days 0.005
Ejection Fraction 0.03
SOV area (cm2) 0.049

 

Presented by A. Linke, MD at EuroPCR 2018

 

Rates of Mild or Greater PVL at 30 days were four times lower with LOTUS.

Rates of Mild or Greater PVL at 30 days were four times higher with Evolut R / CoreValve. Rates of Mild or Greater PVL at 30 days were four times higher with Evolut R / CoreValve.